IP Library Granted Patent US 9,107,928
Granted Patent B2
US 9,107,928 · App. 12/792,393 · Granted Aug 18, 2015

Compositions and methods for treating ophthalmic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,107,928
App. No.
12/792,393
Granted
Aug 18, 2015
Kind
B2
Abstract

The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.

Claims (3)

1. A method for treating an ophthalmic disorder in a subject, comprising administering to said subject a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO. 23, wherein the ophthalmic disorder is macular oedema or retinal ischemia, thereby treating the ophthalmic disorder in said subject.

2. A method for treating macular oedema induced by a retinopathy in a subject, comprising intreavitrally administering to said subject a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO. 23, thereby treating macular oedema induced by a retinopathy in said subject.

3. The method of claim 2 , wherein said retinopathy is a retinal venous occlusion.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2010
From: BELICHARD, PIERRE
To: FOVEA PHARMACEUTICALS
Reel/Frame 024477/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2010
From: FOVEA PHARMACEUTICALS
To: DYAX CORP
Reel/Frame 024477/0885 →